Invention Grant
- Patent Title: Inhibitors of KEAP1-Nrf2 protein-protein interaction
-
Application No.: US17127569Application Date: 2020-12-18
-
Publication No.: US11897900B2Publication Date: 2024-02-13
- Inventor: J. Kent Barbay , Wenying Chai , Gavin C. Hirst , Kevin D. Kreutter , David A. Kummer , Kelly J. McClure , Rachel T. Nishimura , Amy Y. Shih , Jennifer D. Venable , Hariharan Venkatesan , Jianmei Wei
- Applicant: Janssen Pharmaceutica NV
- Applicant Address: BE Beerse
- Assignee: Janssen Pharmaceutica NV
- Current Assignee: Janssen Pharmaceutica NV
- Current Assignee Address: BE Beerse
- Agent Guodong Liu
- Main IPC: C07D513/14
- IPC: C07D513/14 ; C07D519/00 ; C07D515/20 ; C07D513/10 ; C07D515/04 ; C07D513/04 ; C07D471/04 ; C07D419/10 ; C07D515/10
Abstract:
Sultam compounds, pharmaceutical compositions containing them, methods of making them, and methods of using them including methods for treating disease states, disorders, and conditions associated with the KEAP1-Nrf2 interaction, such as inflammatory bowel disease, including Crohn's disease and ulcerative colitis.
Public/Granted literature
- US20220315604A1 INHIBITORS OF KEAP1-Nrf2 PROTEIN-PROTEIN INTERACTION Public/Granted day:2022-10-06
Information query
